NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-23-190 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-042 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-042 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-090 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.
Funding Opportunity RFA-DK-22-511 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from the two previously funded Rare and Atypical DIAbetes NeTwork (RADIANT) research centers to further study rare and atypical forms of diabetes mellitus. These centers will continue to identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of diabetes mellitus in the general population. RADIANT will also continue to develop community resources to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. During this grant cycle, RADIANT will establish precision diagnoses for new Mendelian forms of diabetes by enrolling family members of previously enrolled participants with a family history suggestive of a Mendelian form of diabetes to aid in identifying potential causal variants. In addition, in vitro and basic studies leveraging induced pleuripotent stem cells (iPSCs) differentiated into tissues of interest will be used to establish pathogenicity of potential causal variants.
Funding Opportunity RFA-DA-24-037 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Notice NOT-DK-23-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-22-077 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Leadership Center of the NIAID Consortium for Food Allergy Research (CoFAR). The CoFAR Leadership Center (LC) will define the overall research strategy of the CoFAR including design and oversight of cutting-edge clinical trials and clinical studies to advance prevention and management strategies and to improve knowledge on the origins and the pathophysiology of IgE-mediated food allergy, Alpha-Gal Syndrome, Food Protein-Induced Enterocolitis Syndrome, and Eosinophilic Esophagitis. To achieve its objectives, the CoFAR-LC will work closely and collaborate with the CoFAR Clinical Research Centers (CRCs) to select and implement all CoFAR network-wide clinical trials and studies. The CoFAR-CRCs will be responsible for execution of the CoFAR network-wide clinical trials and studies.
Funding Opportunity RFA-AI-22-076 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Clinical Research Centers (CRC) for the NIAID Consortium for Food Allergy Research (CoFAR). The CoFAR-CRCs will conduct both network-wide observational studies/clinical trials and center-specific projects with the goals to advance prevention and management strategies and to improve knowledge on the origins and the pathophysiology of IgE-mediated food allergy, Alpha-Gal Syndrome, Food Protein-induced Enterocolitis Syndrome and Eosinophilic Esophagitis. For network-wide clinical research projects and other network functions, the CoFAR-CRCs will work closely with the CoFAR Leadership Center (CoFAR-LC). The CoFAR CRCs also will conduct center-specific human research projects.
Notice NOT-CA-23-043 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-004 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-073 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-081 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-23-004 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) Office of Research on Womens Health (ORWH), in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), invite applications for an Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U24 Clinical Trial Not Allowed). The purpose of the AGIE Coordinating Center will be to provide the organizational framework for the management, direction, and overall coordination of all common activities aimed at investigating strategies, approaches, and interventions enabling, and barriers preventing, women to attain leadership positions in many areas of science, technology, and engineering.
Funding Opportunity PAR-23-035 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.
Notice NOT-MD-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-003 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-062 from the NIH Guide for Grants and Contracts